Nanotechnology for Diabetes: A Review
Journal Title: World Journal of Pharmaceutical Sciences - Year 2016, Vol 4, Issue 7
Abstract
This review article discusses the potential applications of nanoparticles and BioMEMS as drug delivery systems for diabetes treatment. This manuscript discusses polymeric nanoparticles, oral insulin administration using polysaccharides and polymeric nanoparticles, inhalable insulin nanoparticles formulations, and insulin delivery using BioMEMS. In addition polymeric nanoparticles and treatment of diabetes –associated symptoms are discussed. There are a few limitations in the use of conventionally available drug delivery systems for diabetes treatment. This article reviews the subject in brief with suitable references to original research articles and review articles on earlier and current research findings about various types of nanoparticles and BioMEMS in diabetes treatment and their limitations.
Authors and Affiliations
Prathiba V
Keywords
Related Articles
- EP ID EP199846
- DOI -
- Views 92
- Downloads 0
Troubleshooting and maintenance of high-performance liquid chromatography- A Review
HPLC (High Performance Liquid Chromatography) has evolved into an indispensable tool in many analytical laboratories and is applied to diverse analytical problems. Troubleshooting HPLC instrumentation and separations req...
Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
Diabetic hypertensives have higher cardiovascular morbidity and mortality than general population. Various risk factors like age, BMI, hypertension, smoking, dyslipidemia, etc. have been extensively studied, but still th...
Levofloxacin Induced Angioedema: A Case Report
Levofloxacin is a broad spectrum antibiotic of the class third generation fluroquinolone. A 48yr old female patient is on levofloxacin antibiotic for fever develop itching and swelling of the eye and leg on the third day...
Formulation, development and evaluation of oil entrapped calcium alginate floating beads of atenolol for antihypertensive drug
Atenolol, a competitive beta (1)-selective adrenergic antagonist, has the lowest lipid solubility of this drug class. Although it is similar to metoprolol, atenolol differs from pindolol and propranolol in that it does n...
Enlightenment on various aspects of neonatal septicemia: An expansive overviewC
The neonatal intensive care units (NICUs) today face one common problem of tackling sepsis and neonatologists remain constantly baffled by the varying patterns of microbial flora and their sensitivity patterns. Neonatal...